85 related articles for article (PubMed ID: 16455165)
1. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels.
Dell K; Koesters R; Linnebacher M; Klein C; Gissmann L
Vaccine; 2006 Mar; 24(13):2238-47. PubMed ID: 16455165
[TBL] [Abstract][Full Text] [Related]
2. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
4. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
[TBL] [Abstract][Full Text] [Related]
5. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Fraillery D; Zosso N; Nardelli-Haefliger D
Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
[TBL] [Abstract][Full Text] [Related]
6. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.
Cho HJ; Kim JY; Lee Y; Kim JM; Kim YB; Chun T; Oh YK
Vaccine; 2010 Mar; 28(14):2598-606. PubMed ID: 20116467
[TBL] [Abstract][Full Text] [Related]
7. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
[TBL] [Abstract][Full Text] [Related]
8. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
[TBL] [Abstract][Full Text] [Related]
10. Combined oral/nasal immunization protects mice from Sendai virus infection.
Nedrud JG; Liang XP; Hague N; Lamm ME
J Immunol; 1987 Nov; 139(10):3484-92. PubMed ID: 2824609
[TBL] [Abstract][Full Text] [Related]
11. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine.
Walsh EE
J Infect Dis; 1994 Aug; 170(2):345-50. PubMed ID: 8035021
[TBL] [Abstract][Full Text] [Related]
12. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
13. Induction of IgA and IgG antibodies in vaginal fluid, serum and saliva following immunization of genital and gut associated lymphoid tissue.
Bergmeier LA; Tao L; Gearing AJ; Adams S; Lehner T
Adv Exp Med Biol; 1995; 371B():1567-73. PubMed ID: 7502858
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunization after intranasal coadministration of Escherichia coli heat-labile enterotoxin B subunit and human papillomavirus 16-L1 DNA vaccine.
Wang J; Zhao CA; Wang K; Zheng J; Wang YL; Si LS
Chin Med J (Engl); 2006 Mar; 119(5):408-11. PubMed ID: 16542585
[No Abstract] [Full Text] [Related]
15. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus.
Muller CP; Beauverger P; Schneider F; Jung G; Brons NH
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1371-80. PubMed ID: 7782766
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
17. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
18. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.
Cuburu N; Kweon MN; Hervouet C; Cha HR; Pang YY; Holmgren J; Stadler K; Schiller JT; Anjuère F; Czerkinsky C
J Immunol; 2009 Dec; 183(12):7851-9. PubMed ID: 19933861
[TBL] [Abstract][Full Text] [Related]
19. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
Price GA; Russell MW; Cornelissen CN
Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
[TBL] [Abstract][Full Text] [Related]
20. The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization.
Fang Y; Zhang T; Lidell L; Xu X; Lycke N; Xiang Z
Mucosal Immunol; 2013 Nov; 6(6):1168-78. PubMed ID: 23571505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
